Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28236099 | 0.84 | LMNA (0.37) | TSHRALDH1A1L3MBTL1THRBCA2 | |
| Trifluoroacetic Acid SCHEMBL1628375 | 0.83 | ALDH1A1 (0.36) | TSHRALDH1A1L3MBTL1THRBCA2 | |
| Trifluoroacetic Acid SCHEMBL1262416 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL3499424 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL72727 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL2484766 | 0.82 | ALDH1A1 (0.44) | TSHRALDH1A1L3MBTL1THRBCA2 | |
| Trifluoroacetic Acid SCHEMBL4598430 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL7814389 | 0.82 | ALDH1A1 (0.44) | TSHRALDH1A1L3MBTL1THRBCA2 | |
| Trifluoroacetic Acid SCHEMBL474 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL30657022 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638441-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4624465-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2025-10-01 | — | — | EP | disclosed |
| CN-120131691-A | Anti-tumor combined pharmaceutical composition and application thereof | 上海齐鲁制药研究中心有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024193640-A1 | CDK INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2024-09-26 | — | — | WO | disclosed |
| WO-2024133499-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2024-06-27 | — | — | WO | disclosed |
| CN-118005640-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-111918651-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117425649-A | Pyrazole derivatives as KRAS mutein inhibitors | 诺华股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-112867721-B | STING agonistic compounds | 小野药品工业株式会社 | 2023-12-08 | — | — | CN | disclosed |
| CN-116209663-A | Methods and compositions for targeting PD-L1 | 安力高医药股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115873069-A | Peptide amide compound, pharmaceutically acceptable salt and stereoisomer thereof, and application thereof | 天地恒一制药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115715289-A | Polyarylate and use thereof | 江苏先声药业有限公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-115707712-A | Peptide amide compound, pharmaceutically acceptable salt and stereoisomer thereof, and application thereof | 天地恒一制药股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-3340981-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022197641-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-AMINE DERIVATIVES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS AND/OR INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | RAPT THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | TSHR 4605/4885ALDH1A1 823/4885L3MBTL1 1302/4885 |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, MCL1, DTYMK | TSHR 4605/4885ALDH1A1 823/4885L3MBTL1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.